You are here
ASKLEPIOS BIOPHARMACEUTICAL, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
Amount: $270,008.00Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International' ...
STTRPhase I2014Department of Health and Human Services National Institutes of Health -
Preclinical Development of AAV-Galanin for Epilepsy
Amount: $282,210.00DESCRIPTION (provided by applicant): This proposal seeks to leverage proprietary technical advances in Adeno-Associated Virus (AAV) vector mediated gene therapy to develop an AAV based Galanin gene de ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Preclinical Studies Supporting Phase Ib Study of Minidystrophin Gene in AAV Vecto
Amount: $2,694,020.00DESCRIPTION (provided by applicant): This proposal intends to advance the regional delivery of a chimeric adeno-associated virus (rAAV)-based, highly-truncated dystrophin (minidystrophin) gene therapy ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
rAAV Revitalized Structural Allografts
Amount: $157,070.00DESCRIPTION (provided by applicant): Repair of large structural bone defects remains a major problem in orthopaedic reconstruction surgery due to the limited supply of cortical bone autograft and the ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health